On-Call Symptom Interventions for Patients Receiving Bispecific T-Cell Engagers
Last Updated: July 1, 2025
On-Call Symptom Interventions for Patients Receiving Bispecific T-Cell Engagers (Mid-sized, Community Cancer Clinic)
Find Similar Resources:
Immunotherapy
Immunotherapy
Immunotherapy
Immunotherapy
Example SOPs and Documents: Transitioning Patients on Bispecific T-Cell Engagers Between Care Settings
Last Updated: 08/10/2025
Example SOPs and Documents: Bispecific T-cell Engager Billing Procedure
Last Updated: 08/10/2025
Example SOPs and Documents: Bispecific T-Cell Engager Ordering and REMS Compliance
Last Updated: 08/10/2025
Example SOPs and Documents: On-Call Responsibilities for Nurses Managing Bispecific T-Cell Engagers
Last Updated: 08/10/2025
PQI
PQI
PQI in Action
PQI
PQI: Prophylaxis and Management of Skin Toxicities with Amivantamab (Rybrevant) and Lazertinib (Lazcluze) Treatment: The COCOON Protocol
Author: Sharon Zhong, PharmD, BCOP
Last Updated: 08/10/2025
PQI: Encorafenib (Braftovi®) and Binimetinib (Mektovi®) for the Management of NSCLC
Author: Aubrey Lasko, PharmD, BCOP
Last Updated: 08/10/2025
PQI in Action: Management of Tucatinib (Tukysa®) and Trastuzumab in HER2-Positive Metastatic Colorectal Cancer – 2
Author: Johns Hopkins, MD | The University of Texas MD Anderson Cancer Center, TX
Last Updated: 08/10/2025
PQI: Bone Health and the Cancer Patient
Author: Nina DiPierro Pharm.D. BCOP, Florida Cancer Specialists and Research Institute | Farishta Manzoor, PharmD, Hartford HealthCare Cancer Institute
Last Updated: 08/10/2025